• News
  • SAN DIEGO
  • BioTech

Celladon appoints Michael Narachi as board chairman

Celladon Corp., a San Diego-based clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, Friday announced it has appointed Michael Narachi as chairman of the board of directors.

Narachi currently serves as president and CEO of Orexigen Therapeutics Inc. (Nasdaq: OREX).

He has 29 years of biotechnology and pharmaceutical experience across a broad range of functions, including clinical development, commercialization, strategic business development and planning.

Prior to joining Orexigen, Narachi served as chairman, CEO and president of Ren Pharmaceuticals Inc., a private biotechnology company, and executive chairman of the board of Naryx Pharma Inc., a private pharmaceutical company.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Orexigen Therapeutics Inc.

Company Website

3344 North Torrey Pines Ct. Ste., 200
La Jolla, CA 92037

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
OREX
3.02
  0.19  
+ 6.71%
9,938,773,000
9.37
1.84

Orexigen Therapeutics Inc. Executive(s):

Michael Narachi

  • Chief Executive Officer, President

Similar Companies

Subscribe Today!